Cullinan Therapeutics, Inc. (CGEM)
- Previous Close
26.57 - Open
27.10 - Bid 26.09 x 200
- Ask 26.17 x 400
- Day's Range
26.07 - 27.59 - 52 Week Range
7.64 - 30.19 - Volume
689,385 - Avg. Volume
733,826 - Market Cap (intraday)
1.125B - Beta (5Y Monthly) -0.00
- PE Ratio (TTM)
-- - EPS (TTM)
-3.69 - Earnings Date Aug 8, 2024 - Aug 12, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
33.14
Cullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib. Cullinan Therapeutics, Inc. was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
cullinantherapeutics.comRecent News: CGEM
Performance Overview: CGEM
Trailing total returns as of 5/13/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CGEM
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CGEM
Valuation Measures
Market Cap
1.14B
Enterprise Value
680.78M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
2.52
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-1.46
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-22.80%
Return on Equity (ttm)
-31.37%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-153.16M
Diluted EPS (ttm)
-3.69
Balance Sheet and Cash Flow
Total Cash (mrq)
467.07M
Total Debt/Equity (mrq)
0.79%
Levered Free Cash Flow (ttm)
-88.76M
Research Analysis: CGEM
Company Insights: CGEM
CGEM does not have Company Insights